Ribomic

Ribomic EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ribomic (4591.T) as of Oct 30, 2026 is -1.21 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.05 B JPY — a change of 15.00% (lower).

EBITDA

-1.21 BJPY

YoY

15.00%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ribomic is 2026 -1.21 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ribomic was 2025 -1.05 B JPY. It decreases by 15.00% lower compared to the previous year.

The Ribomic EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-926.41 M JPY
Jan 1, 2020
-912.93 M JPY
Jan 1, 2021
-1.21 B JPY
Jan 1, 2022
-1.73 B JPY
Jan 1, 2023
-1.79 B JPY
Jan 1, 2024
-1.11 B JPY
Jan 1, 2025
-1.05 B JPY
Jan 1, 2026
-1.21 B JPY
The Ribomic EBITDA history
YEAREBITDAYoY
-1.21 BJPY+15.00%
-1.05 BJPY-5.07%
-1.11 BJPY-38.08%
-1.79 BJPY+3.06%
-1.73 BJPY+42.85%
-1.21 BJPY+32.86%
-912.93 MJPY-1.45%
-926.41 MJPY+3.14%
-898.19 MJPY+14.51%
-784.38 MJPY+47.46%
-531.91 MJPY-7,814.46%
6.90 MJPY-101.17%
-589.68 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ribomic is -1.21 B JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ribomic changed from -1.05 B JPY to -1.21 B JPY, representing a 15.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Ribomic since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Ribomic

All Key Metrics — Ribomic